Trial · NCT00413699
Results by group2,184
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 2,184
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 5 Milligram(mg) Twice Daily (BID) | Participants with non-serious AEs | 991 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 10 mg BID | Participants with non-serious AEs | 2963 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: All Tofacitinib | Participants with non-serious AEs | 3954 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 5 Milligram(mg) Twice Daily (BID) | Blood and lymphatic system disorders | 159 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 10 mg BID | Blood and lymphatic system disorders | 395 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: All Tofacitinib | Blood and lymphatic system disorders | 554 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 5 Milligram(mg) Twice Daily (BID) | Cardiac disorders | 93 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 10 mg BID | Cardiac disorders | 185 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: All Tofacitinib | Cardiac disorders | 278 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 5 Milligram(mg) Twice Daily (BID) | Congenital, familial and genetic disorders | 6 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 10 mg BID | Congenital, familial and genetic disorders | 16 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: All Tofacitinib | Congenital, familial and genetic disorders | 22 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 5 Milligram(mg) Twice Daily (BID) | Ear and labyrinth disorders | 67 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 10 mg BID | Ear and labyrinth disorders | 138 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: All Tofacitinib | Ear and labyrinth disorders | 205 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 5 Milligram(mg) Twice Daily (BID) | Endocrine disorders | 29 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 10 mg BID | Endocrine disorders | 94 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: All Tofacitinib | Endocrine disorders | 123 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 5 Milligram(mg) Twice Daily (BID) | Eye disorders | 117 | Number of participants | |
| Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports | Initial Period: Tofacitinib 10 mg BID | Eye disorders | 259 | Number of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00413699/results